Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19)

TCF Yip, GCY Lui, MSM Lai, VWS Wong… - Clinical infectious …, 2023 - academic.oup.com
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …
被引用次数：81 相关文章

Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19).

TCF Yip, GCY Lui, MSM Lai, VWS Wong, YK Tse… - 2022 - cabidigitallibrary.org
Background: We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients

TCF Yip, GCY Lui, MSM Lai, VWS Wong… - … Infectious Diseases: An … - ncbi.nlm.nih.gov
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of non-hospitalized COVID-19 …

Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).

TCF Yip, GCY Lui, MSM Lai… - Clinical Infectious …, 2023 - search.ebscohost.com
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)

TCF Yip, GCY Lui, MSM Lai, VWS Wong… - Clinical Infectious …, 2023 - academic.oup.com
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).

TC Yip, GC Lui, MS Lai, VW Wong, YK Tse… - … Diseases: an Official …, 2023 - europepmc.org
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalisation in Community COVID-19 Patients

CF Yip, GCY Lui, MS Man Lai, VWS Wong… - Available at SSRN … - papers.ssrn.com
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalisation and deaths in a real-world cohort of non-hospitalised COVID-19 …

Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)

TCF Yip, GCY Lui, MSM Lai… - … publication of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients.

TCF Yip, GCY Lui, MSM Lai, VWS Wong… - … Diseases: an Official …, 2022 - europepmc.org
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of non-hospitalized COVID-19 …